IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Results of Operations and Financial Condition

IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Results of Operations and Financial Condition
Item 2.02

On February 27, 2019, Ionis Pharmaceuticals, Inc. (the Company) issued a press release announcing the Companys financial results for the quarter and fiscal year ended December 31, 2018. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (GAAP), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation related to stock awards. The Company is presenting pro forma information excluding non-cash compensation because the Company believes it is useful for investors in assessing the Companys operating results compared to the prior year. A copy of the release is furnished with this report as an exhibit to Item 2.02. Results of Operations and Financial Condition of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583.
The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Ionis Exceeds 2018 Financial Guidance Total revenue increased 17% compared to 2017 to $600 million Commercial revenues more than doubled Conference call and webcast today,…
To view the full exhibit click here

Story continues below


Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform. The Company’s Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

An ad to help with our costs